Picture of GoodRx Holdings logo

GDRX — GoodRx Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyAdventurousMid CapSuper Stock

GoodRx Q4 revenue slightly beats estimates, helped by Pharma Direct growth

Overview

Medication savings platform's Q4 revenue slightly beat analyst expectations

Adjusted EBITDA for Q4 slightly exceeded analyst estimates

Pharma Direct revenue grew over 40% yr/yr, beating previous company outlook

Outlook

GoodRx anticipates 2026 revenue between $750 mln and $780 mln

Company expects 2026 adjusted EBITDA to exceed $230 mln

GoodRx prioritizes preserving margin strength and reinforcing platform durability in 2026

Result Drivers

PHARMA DIRECT GROWTH - Pharma Direct revenue increased over 40% yr/yr, driven by expanded market penetration and consumer direct pricing

RETAIL PHARMACY CHANGES - Prescription transactions revenue decreased due to retail pharmacy changes, including store closures and volume reduction in savings programs

SUBSCRIPTION DECLINE - Subscription revenue decreased due to a reduction in the number of subscription plans

Company press release: ID:nBw7mmtywa

Key Details

MetricBeat/MissActualConsensus Estimate
Q4 RevenueSlight Beat*$194.80 mln$193.26 mln (12 Analysts)
Q4 Adjusted Net IncomeMiss$29 mln$31.96 mln (10 Analysts)
Q4 Net Income$5.40 mln
Q4 Adjusted EBITDASlight Beat*$65 mln$64.85 mln (12 Analysts)
Q4 Adjusted EBITDA Margin33.40%
*Applies to a deviation of less than 1%; not applicable for per-share numbers. Analyst Coverage The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 7 "hold" and 2 "sell" or "strong sell" The average consensus recommendation for the online services peer group is "buy." Wall Street's median 12-month price target for GoodRx Holdings Inc is $4.25, about 79.3% above its February 24 closing price of $2.37 The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 8 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on GoodRx Holdings

See all news